DUPAC reflects our visionary foresight into the future landscape of ADC innovation. We are building DUPAC to develop linker-payload complexes with novel mechanisms of action beyond traditional cytotoxic agents to combat growing drug resistance and hard-to-treat tumors. We have made promising progress in a number of unique payload mechanism and have obtained prototypes with broad-spectrum anti-tumor activity across multiple solid tumors, and potent direct and bystander killing effects in preclinical studies.

· Duality Unique Payload Antibody Conjugate

· 1 preclinical asset

· Potential to overcome resistance to Dxd (TOP1i)

· Targeting hard-to-treat tumor types

· Potential to reshape the ADC treatment